Stocks News

LAST PRICE
155.1850
TODAY'S CHANGE (%)
Trending Down-2.8050 (-1.7754%)

Bid / Lots
154.9500/ 2
Ask / Lots
155.3100/ 2
Open / Previous Close
156.7600 / 157.9900
Day Range
Low 154.0850
High 158.6037
52 Week Range
Low 82.0900
High 189.9700
Volume
69,607
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Apr 26, 2024
- Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024, from 7:00AM ET on Friday Apr 26, 2024 by GlobeNewswire
  7:00AM ET on Friday Apr 26, 2024 by GlobeNewswire
  Companies Mentioned: KRYS
- Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024, from 7:00AM ET on Friday Apr 26, 2024 by Dow Jones
  7:00AM ET on Friday Apr 26, 2024 by Dow Jones
  Companies Mentioned: KRYS
  
  Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024
  
  PITTSBURGH, April 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2024 financial results on Monday, May 6, 2024, prior to the open of U.S. markets.
Apr 22, 2024
- DJ Krystal Biotech Price Target Maintained With a $200.00/Share by HC Wainwright & Co., from 1:58PM ET on Monday Apr 22, 2024 by Dow Jones
  1:58PM ET on Monday Apr 22, 2024 by Dow Jones
  Companies Mentioned: KRYS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/KRYS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  April 22, 2024 13:58 ET (17:58 GMT)
- Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung, from 7:00AM ET on Monday Apr 22, 2024 by GlobeNewswire
  7:00AM ET on Monday Apr 22, 2024 by GlobeNewswire
  Companies Mentioned: KRYS
- Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung, from 7:00AM ET on Monday Apr 22, 2024 by Dow Jones
  7:00AM ET on Monday Apr 22, 2024 by Dow Jones
  Companies Mentioned: KRYS
  
  Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung
  
  -- Received Fast Track Designations for both inhaled and intratumoral KB707

Yesterday
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRC, HRT, ALPN, MCBC, from 15 hours ago by PR Newswire
  15 hours ago by PR Newswire
  Companies Mentioned: MCBC, HRT, ALPN
Apr 27, 2024
- SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN, from 8:47AM ET on Saturday Apr 27, 2024 by GlobeNewswire
  8:47AM ET on Saturday Apr 27, 2024 by GlobeNewswire
  Companies Mentioned: MODN, AIRC, ALPN
Apr 24, 2024
- Madrigal Statement on the Passing of Dr. Stephen Harrison, from 4:00PM ET on Wednesday Apr 24, 2024 by GlobeNewswire
  4:00PM ET on Wednesday Apr 24, 2024 by GlobeNewswire
  Companies Mentioned: MDGL
Apr 23, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIRC, ALPN, WIRE, from 12:05PM ET on Tuesday Apr 23, 2024 by PR Newswire
  12:05PM ET on Tuesday Apr 23, 2024 by PR Newswire
  Companies Mentioned: WIRE, AIRC, ALPN
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024, from 8:00AM ET on Tuesday Apr 23, 2024 by GlobeNewswire
  8:00AM ET on Tuesday Apr 23, 2024 by GlobeNewswire
  Companies Mentioned: MDGL
Apr 22, 2024
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, LABP, SWAV, FUSN, from 6:46PM ET on Monday Apr 22, 2024 by Accesswire
  6:46PM ET on Monday Apr 22, 2024 by Accesswire
  Companies Mentioned: SWAV, FUSN, LABP, ALPN
- TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN, from 5:33PM ET on Monday Apr 22, 2024 by GlobeNewswire
  5:33PM ET on Monday Apr 22, 2024 by GlobeNewswire
  Companies Mentioned: SWAV, FUSN, LABP, ALPN
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN, from 11:13AM ET on Monday Apr 22, 2024 by GlobeNewswire
  11:13AM ET on Monday Apr 22, 2024 by GlobeNewswire
  Companies Mentioned: AIRC, ELYM, ALPN
- Kuehn Law Encourages INRD, AIRC, ELYM, and ALPN Investors to Contact Law Firm, from 9:48AM ET on Monday Apr 22, 2024 by GlobeNewswire
  9:48AM ET on Monday Apr 22, 2024 by GlobeNewswire
  Companies Mentioned: AIRC, ELYM, ALPN
- --BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective, from 9:46AM ET on Monday Apr 22, 2024 by MT Newswires
  9:46AM ET on Monday Apr 22, 2024 by MT Newswires
  Companies Mentioned: MDGL

Krystal Biotech Inc
NASDAQ:KRYSUnited States

Search Criteria

Apr 26, 2024

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024, from 7:00AM ET on Friday Apr 26, 2024 by GlobeNewswire

Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024, from 7:00AM ET on Friday Apr 26, 2024 by Dow Jones

Apr 22, 2024

DJ Krystal Biotech Price Target Maintained With a $200.00/Share by HC Wainwright & Co., from 1:58PM ET on Monday Apr 22, 2024 by Dow Jones

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung, from 7:00AM ET on Monday Apr 22, 2024 by GlobeNewswire

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung, from 7:00AM ET on Monday Apr 22, 2024 by Dow Jones

Peers Headlines

Yesterday

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CRC, HRT, ALPN, MCBC, from 15 hours ago by PR Newswire

Apr 27, 2024

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN, from 8:47AM ET on Saturday Apr 27, 2024 by GlobeNewswire

Apr 24, 2024

Madrigal Statement on the Passing of Dr. Stephen Harrison, from 4:00PM ET on Wednesday Apr 24, 2024 by GlobeNewswire

Apr 23, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AIRC, ALPN, WIRE, from 12:05PM ET on Tuesday Apr 23, 2024 by PR Newswire

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024, from 8:00AM ET on Tuesday Apr 23, 2024 by GlobeNewswire

Apr 22, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALPN, LABP, SWAV, FUSN, from 6:46PM ET on Monday Apr 22, 2024 by Accesswire

TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUSN, from 5:33PM ET on Monday Apr 22, 2024 by GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INRD, AIRC, ELYM, ALPN, from 11:13AM ET on Monday Apr 22, 2024 by GlobeNewswire

Kuehn Law Encourages INRD, AIRC, ELYM, and ALPN Investors to Contact Law Firm, from 9:48AM ET on Monday Apr 22, 2024 by GlobeNewswire

--BofA Securities Initiates Coverage of Madrigal Pharmaceuticals with Underperform Rating, $150 Price Objective, from 9:46AM ET on Monday Apr 22, 2024 by MT Newswires